ViiV Healthcare has committed to tripling the supply of its long-acting cabotegravir formulation used as a pre-exposure prophylactic for HIV prevention in low-and middle-income countries between 2025 and 2026.
Marketed under the name Apretude, the long-acting HIV prophylactic was approved by the US Food and Drug Administration in December 2021
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?